Dragonboat Biopharmaceutical Company Limited

Quick facts

Phase 2 pipeline

• anti-EGFR monoclonal antibody
• BC006 · Oncology
  BC006 is a monoclonal antibody targeting the PD-1 receptor.

Phase 1 pipeline

• CDP1
• TIP chemotherapy

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Dragonboat Biopharmaceutical Company Limited portfolio CI brief
• Dragonboat Biopharmaceutical Company Limited pipeline updates RSS